Skip to main content


Figure 1 | Molecular Medicine

Figure 1

From: Preclinical Studies in the mdx Mouse Model of Duchenne Muscular Dystrophy with the Histone Deacetylase Inhibitor Givinostat

Figure 1

Givinostat treatment of human skeletal myoblasts increases myotube size. The myogenic potential of human skeletal myoblasts was assessed after 24 h of TSA (50 nmol/L) and givinostat (150 nmol/L) in vitro treatment. Representative images of MyHC (red) staining are shown. Nuclei were counterstained with DAPI (4′,6-diamidino-2-phenylindole; Sigma-Aldrich) (blue).

Back to article page